A Phase 1 interventional study of CKD-841 A-1 3.75mg and CKD-841 A-1 1.88mg in Early Puberty, sponsored by Chong Kun Dang Pharmaceutical. Status unknown at 1 site in Korea, Republic of. Open to female participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-19.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing leuprolide in Puberty, Precocious — 2 open to participants now, 2 under way, 1 of them phase 3. Leuprolide · Puberty, Precocious.
Among the 14 studies testing leuprolide in Puberty, Precocious, this one is the 13th largest by planned enrollment, is the only one that started in 2021, is one of 2 in phase 1, and was the 12th registered.
75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.
Browse Puberty, Precocious studies →2 of the 14 studies testing leuprolide in Puberty, Precocious are open now, in 1 country. Recruiting first, the newest first:
LG Chem · Sites in Korea, Republic of
Ages up to 10
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 4–10
By country, each count listing its studies:
Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 40 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 1 started in 2021.
This study's planned enrollment of 32 is below the median of 64 across 47 interventional studies indexed under Puberty, Precocious.
Median enrollment 68 across the 14 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 10 most frequent:
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.
Chong Kun Dang Pharmaceutical has 1 study filed under Puberty, Precocious — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing leuprolide in Puberty, Precocious, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A randomized, single-blinded, parallel design phase I clinical trial to investigate the safety and pharmacokinetics/pharmacodynamics of CKD-841 A-1, CKD-841 D or Leuplin Inj. after subcutaneous injection in postmenopausal female
To investigate the safety and pharmacokinetics/pharmacodynamics of CKD-841 A-1, CKD-841 D or Leuplin Inj. 3.75 mg after subcutaneous injection in postmenopausal female
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug(=CKD-841 A-1) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
Drug: CKD-841 A-1 3.75mg
Investigational drug(=CKD-841 A-1) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
Drug: CKD-841 A-1 1.88mg
Investigational drug(=CKD-841 D) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
Drug: CKD-841 D 2.92mg
Investigational drug(=Leuplin Inj.)is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
Drug: Leuplin Inj. 3.75 mg
Single injection, subcutaneous injection
Also known as: CKD-841
Single injection, subcutaneous injection
Also known as: CKD-841
Single injection, subcutaneous injection
Also known as: CKD-841
Single injection, subcutaneous injection
Also known as: Leuplin.Inj
PK(Cmax)
Cmax(Maximum concentration of drug in plasma) of Leuprorelin
Time frame: From before injection to up to 1008 hours post injection
PK(AUClast)
AUClast(Area under the plasma drug concentration-time curve to last measurement) of Leuprorelin
Time frame: From before injection to up to 1008 hours post injection
PK(AUCinf)
AUCinf(Area under the plasma drug concentration-time curve extrapolated to infinity) of Leuprorelin
Time frame: From before injection to up to 1008 hours post injection
PK(AUC7-t)
AUC7-t(Area under the plasma drug concentration-time curve from 7 days to last measurement) of Leuprorelin
Time frame: From before injection to up to 1008 hours post injection
PK(CL/F)
CL/F(Apparent Clearance) of Leuprorelin
Time frame: From before injection to up to 1008 hours post injection
PK(Vd/F)
Vd/F(Apparent Volume of Distribution) of Leuprorelin
Time frame: From before injection to up to 1008 hours post injection
PK(Tmax)
Tmax(Time to Cmax/Time to Emax) of Leuprorelin
Time frame: From before injection to up to 1008 hours post injection
PK(t1/2)
t1/2(Terminal elimination half-life) of Leuprorelin
Time frame: From before injection to up to 1008 hours post injection
PD(AUEC0-42d below baseline)
AUEC0-42d below baseline((AUEC that is below the baseline from 0 h to 42 days)) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.
Time frame: From before injection to up to 1008 hours post injection
PD(AUEC0-28d below baseline)
AUEC0-28d below baseline(AUEC that is below the baseline from 0 h to 28 days) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.
Time frame: From before injection to up to 1008 hours post injection
PD(Area under the response (% change from baseline) curve)
AUEC(Area under the response (% change from baseline) curve) above baseline of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.
Time frame: From before injection to up to 1008 hours post injection
PD(Tmax)
Tmax(Time to Cmax/Time to Emax) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.
Time frame: From before injection to up to 1008 hours post injection
PD(Tmin)
Tmin(Time to Emin) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.
Time frame: From before injection to up to 1008 hours post injection
PD(Emax)
Emax(Maximum % change from baseline of LH/FSH/Estradiol) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.
Time frame: From before injection to up to 1008 hours post injection
PD(Emin)
Emin(Minimum % change from baseline of LH/FSH/Estradiol) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.
Time frame: From before injection to up to 1008 hours post injection
Safety Assessment by evaluating adverse events(AEs).
Assessment of the safety of subjects by evaluating adverse events(AEs).
Time frame: From day1 to day 56
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2021; primary completion for Oct 2021, 6 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leuprolide
Chong Kun Dang Pharmaceutical →